Keywords
rheumatoid
physiopathology
prevalence
early diagnosis
early medical intervention
antirheumatic agents
drug monitoring
artificial intelligence
How to Cite
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints due to an erroneous attack by the immune system. RA development is influenced by genetic, hormonal, immunological and environmental factors, whose understanding is crucial to improve treatments. Materials and Methods: Reports published in PubMed, Scielo and Google Scholar between 2010-2023 were reviewed, using keywords such as “rheumatoid arthritis” and “early diagnosis”, and others, considering publications in English and Spanish. Results: RA is diagnosed through autoantibodies, inflammatory markers and radiographic, ultrasound and magnetic resonance images. Symptoms are controlled by nonsteroidal anti-inflammatory drugs and glucocorticoids, while therapy has been transformed by disease-modifying antirheumatic drugs. RA management can be optimized using artificial intelligence, through analysis of omic and clinical data. Discussion: The clinical management of RA has been improved by new therapies and biomarkers. The goal is to develop curative and preventative treatments that transform RA into a manageable disease.
References
1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 ;365(23):2205–19, https://doi.org/10.1056/nejmra1004965
2. FEFARA Federación Farmacéutica; 2023. Día Mundial de la Artritis Reumatoidea. Disponible en: https://www.fefara.org.ar/12-de-octubredia-mundial-de-la-artritis-reumatoidea/
3. Wasserman A. Rheumatoid Arthritis: Common Questions About Diagnosis and Management. Am Fam Physician 2018 1;97(7). https://pubmed.ncbi.nlm.nih.gov/29671563/
4. Gravallese EM, Firestein GS. Rheumatoid Arthritis - Common Origins, Divergent Mechanisms. N Engl J Med. 2023 ;388(6):529–42. https://doi.org/10.1056/NEJMra2103726
5. Patel JP, Konanur Srinivasa NK, Gande A, Anusha M, Dar H, Baji DB. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. Cureus. 2023 (1):e33293. https://doi.org/10.7759/cureus.33293
6. Mateen S, Zafar A, Moin S, Khan AQ, Zubair S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta. 2016; 455:161–71. https://doi.org/10.1016/j.cca.2016.02.010
7. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007 (3):281–6. https://doi.org/10.1016/j.coi.2007.04.005
8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584
9. Findeisen KE, Sewell J, Ostor AJK. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics. 2021;15:343–52. https://doi.org/10.2147/btt.s252575
10. Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells 2020;9(4). https://doi.org/10.3390/cells9040880
11. Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021 Oct 23;10(11).Disponible desde: http://dx.doi.org/10.3390/cells10112857
12. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924–39. https://doi.org/10.1002/acr.24596
13. GUIPCAR: guía de práctica clínica para el manejo de la artritis reumatoide en España. 2001. 230 p.
14. Leslie Escobar QF. Monitorización terapéutica de fármacos y aspectos prácticos de farmacocinética. Rev médica Clín Las Condes. 2016;27(5):605–14. https://doi.org/10.1016/j.rmclc.2016.09.006
15. Krieckaert C, Hernández-Breijo B, Gehin JE, le Mélédo G, Balsa A, Jani M, et al. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. 2022 1;8(2):e002216. https://doi.org/10.1136/rmdopen-2022-002216
16. Momtazmanesh S, Nowroozi A, Rezaei N. Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-ofthe-Art Review. Rheumatol Ther. 2022;9(5):1249–304. https://doi.org/10.1007/s40744-022-00475-4